EMJ GOLD: Pharma news, views and analysis

This week, Marc and Helena are back together in the studio once more, and to mark the midpoint of season two, GOLD's Assistant Editor, Isabel O'Brien, joins them to check in on our guests' predictions for 2022. Hear from Julie Ross, Kay Wesley and Jennifer Cain Birkmose as the team pours over their predictions to see if clinical trials have been drastically decentralised, whether hybrid events are here to stay and if pharma's pandemic push for collaboration has continued. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Remote trials: replicating reality https://www.emg-gold.com/post/remote-trials-replicating-reality Interview with Claire Skentelbery https://www.emg-gold.com/post/podcast-claire-skentelbery-director-general-europabio Interview with Judy Stewart https://www.emg-gold.com/post/we-ve-lost-the-focus-that-we-had-on-routine-vaccination-of-preventable-diseases

In this episode, GOLD is joined by Davidek Herron, Global Head of Digital, Roche, who discusses his journey from professional basketball player to pharma leader, including the lessons he has taken from sport into business. He also shares his unique take on digital transformation and the secret to job satisfaction. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: A Cautionary Tale https://www.emg-gold.com/post/a-cautionary-tale "We've lost the focus that we had on routine vaccination of preventable diseases" https://www.emg-gold.com/post/we-ve-lost-the-focus-that-we-had-on-routine-vaccination-of-preventable-diseases A Debate On Digital Transformation https://www.emg-gold.com/post/a-debate-on-digital-transformation "We need to create an equitable experience for all" https://www.emg-gold.com/post/we-need-to-create-an-equitable-experience-for-all

In this episode, GOLD is joined by Magnus Björsne, CEO, AstraZeneca BioVentureHub, who discusses the impact of the pandemic on innovation, collaboration and creativity within the industry. This episode also features a special diabetes-focused 'Things you might have missed', with news on novel management and monitoring technology for people living with diabetes. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Nurturing home-grown innovation in Europe https://www.emg-gold.com/post/nurturing-home-grown-innovation-in-europe A recipe for success in European healthcare https://www.emg-gold.com/post/a-recipe-for-success-in-european-healthcare A big boom in biotech https://www.emg-gold.com/post/a-big-boom-in-biotech The risks, rewards and future potential of biotechnology https://www.emg-gold.com/post/podcast-the-risks-rewards-and-future-potential-of-biotechnology

In this episode, GOLD is joined by Isabel Afonso, General Manager, Novartis Oncology China, who shares insights on the pharmaceutical landscape of the country and the potential of partnerships with multinational corporations, followed by a conversation with Dr Farid Khan, CEO and Founder, PharmaKure, about the vital ongoing need for drug development and the scientific details behind biopharmaceuticals. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Pharma in… China https://www.emg-gold.com/post/pharma-in-china A big boom in biotech https://www.emg-gold.com/post/a-big-boom-in-biotech A heyday for mRNA https://www.emg-gold.com/post/a-heyday-for-mrna The vast galaxy of neurology https://www.emg-gold.com/post/the-vast-galaxy-of-neurology

In this bonus episode, GOLD brings you the full feature-length interview with Claire Skentelbery, Director General, EuropaBio. She explores the contribution that biotech will have on Europe's future and economic footprint, the preparedness of Europe to deliver biotech's innovative therapies at scale, as well as the investment landscape for biotech-related SMEs. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: A big boom in biotech https://www.emg-gold.com/post/a-big-boom-in-biotech Nurturing homegrown innovation in Europe https://www.emg-gold.com/post/nurturing-home-grown-innovation-in-europe The hard sell of cell and gene therapies https://www.emg-gold.com/post/the-hard-sell-of-cell-and-gene-therapies

In this episode, we speak to Claire Skentelbery, Director General, EuropaBio, about the biotech revolution, including how biotech companies could contribute to the European economy in the future and the readiness of Europe to deliver these innovative solutions at scale. The GOLD team also discusses the biotech revolution from an investor's perspective, exploring the risks and rewards of investing in therapies driven by biotechnology. Click here to subscribe to the weekly newsletter for more insights from GOLD. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: A big boom in biotech https://www.emg-gold.com/post/a-big-boom-in-biotech Nurturing homegrown innovation in Europe https://www.emg-gold.com/post/nurturing-home-grown-innovation-in-europe The hard sell of cell and gene therapies https://www.emg-gold.com/post/the-hard-sell-of-cell-and-gene-therapies

In this episode, Dr Nigel Guest, CEO, Trifolium Consulting, speaks to GOLD about his experiences as a GP during the pandemic, interactions with the pharma field force and his thoughts on the future of preventative medicines. Helena and Isabel additionally discuss the importance of making disease awareness campaigns really matter. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Pursuing a pathway of prevention https://www.emg-gold.com/post/pursuing-a-pathway-of-prevention Building Campaigns with Communities https://www.emg-gold.com/post/building-campaigns-with-communities Making a Difference in Terminal Diseases https://www.emg-gold.com/post/making-a-difference-in-terminal-diseases The Rare Disease Disparity https://www.emg-gold.com/post/the-rare-disease-disparity

In this special bumper episode to mark International Women's Day, Helena is joined by Nikki Jones, Head of Diversity, Equity and Inclusion at the Healthcare Businesswomen's Association, to discuss the role of this global celebration within the health space. The team also speaks to Aliya Omer, Vice President and Head of Global Portfolio and Program Strategy at Kite Pharma, about how she navigated gender biases through her career. And the episode is topped off with a deep dive into GOLD features on gender parity with Isabel O'Brien, Assistant Editor – it's an episode not to be missed! If you're interested in learning more about the topic areas discussed in this episode, check out the following content: A discussion on the pandemic and gender parity https://www.emg-gold.com/post/a-discussion-on-the-pandemic-and-gender-parity Diversity: from ideas to action https://www.emg-gold.com/post/diversity-from-ideas-to-action Mind the pay gap https://www.emg-gold.com/post/mind-the-pay-gap

In this episode, GOLD talks to Liz Ashall-Payne, founder of ORCHA, a company that curates libraries of digital health apps for patients and healthcare professionals. She discusses the growing patient appetite for apps, the education that is needed for healthcare professionals and early considerations for pharma companies wishing to develop these solutions. GOLD also speaks to Dario Safaric, founder of the 'NEXT Pharma' conferences, about the upcoming 'Next Normal' event and pharma's future in the metaverse. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Bridging the digital health divide https://www.emg-gold.com/post/bridging-the-digital-health-divide Spoonful of apps https://www.emg-gold.com/post/spoonful-of-apps Next Normal event https://nextpharmasummit.com/nextnormal/

In this episode, GOLD talks to Wayne Best, Chief Creative Officer, VMLY&R, who offers his insights on the innovative 'I Will Always Be Me' project with the MND Association – a fascinating and important cause with so much potential to inspire the pharma industry. But that's not all! Join us to delve into the latest GOLD infographic on supply chain stability and hear the latest industry news you might have missed. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Risks to supply chain vulnerability – infographic https://www.emg-gold.com/_files/ugd/b8a9db_2fee0c32ea6940e69a36e4d939eedade.pdf Reacting to supply chain risks https://www.emg-gold.com/post/reacting-to-supply-chain-risks AI and Big Data at the forefront of pharma in 2022 https://www.emg-gold.com/post/ai-and-big-data-at-the-forefront-of-pharma-in-2022 The latest GOLD issue, including the blockchain feature mentioned https://go.emg-gold.com/gold-20-access-form